NZ597983A - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors - Google Patents
Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitorsInfo
- Publication number
- NZ597983A NZ597983A NZ597983A NZ59798310A NZ597983A NZ 597983 A NZ597983 A NZ 597983A NZ 597983 A NZ597983 A NZ 597983A NZ 59798310 A NZ59798310 A NZ 59798310A NZ 597983 A NZ597983 A NZ 597983A
- Authority
- NZ
- New Zealand
- Prior art keywords
- furo
- morpholin
- indol
- ylmethyl
- phosphoinositide
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- RKURGBLIJFFUCK-UHFFFAOYSA-N 3-[4-[[2-(1h-indol-4-yl)-4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-8-yl]methyl]piperazin-1-yl]propanenitrile Chemical compound C1CN(CCC#N)CCN1CC1=CN=C(OC=2C3=NC(=NC=2N2CCOCC2)C=2C=4C=CNC=4C=CC=2)C3=C1 RKURGBLIJFFUCK-UHFFFAOYSA-N 0.000 abstract 1
- YFVNYGYEGQOOKR-UHFFFAOYSA-N 8-(azetidin-1-ylmethyl)-2-(1h-indol-4-yl)-4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidine Chemical compound C=1N=C2OC3=C(N4CCOCC4)N=C(C=4C=5C=CNC=5C=CC=4)N=C3C2=CC=1CN1CCC1 YFVNYGYEGQOOKR-UHFFFAOYSA-N 0.000 abstract 1
- HMCURYMZQAWYES-UHFFFAOYSA-N 8-[(4-fluoropiperidin-1-yl)methyl]-2-(1h-indol-4-yl)-4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidine Chemical compound C1CC(F)CCN1CC1=CN=C(OC=2C3=NC(=NC=2N2CCOCC2)C=2C=4C=CNC=4C=CC=2)C3=C1 HMCURYMZQAWYES-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- BGQQVLCGNLFQNJ-UHFFFAOYSA-N n-[[2-(1h-indol-4-yl)-4-morpholin-4-ylpyrido[2,3]furo[2,4-b]pyrimidin-8-yl]methyl]-n-methylcyclopropanamine Chemical compound C1CC1N(C)CC(C=C1C2=NC(=N3)C=4C=5C=CNC=5C=CC=4)=CN=C1OC2=C3N1CCOCC1 BGQQVLCGNLFQNJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0914594A GB0914594D0 (en) | 2009-08-20 | 2009-08-20 | Compounds |
| GBGB1005584.6A GB201005584D0 (en) | 2010-04-01 | 2010-04-01 | Compounds |
| PCT/GB2010/051370 WO2011021038A1 (en) | 2009-08-20 | 2010-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597983A true NZ597983A (en) | 2014-05-30 |
Family
ID=42756474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597983A NZ597983A (en) | 2009-08-20 | 2010-08-19 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9200007B2 (enExample) |
| EP (1) | EP2467387B1 (enExample) |
| JP (1) | JP5746172B2 (enExample) |
| CN (1) | CN102498115B (enExample) |
| AU (1) | AU2010286168B2 (enExample) |
| BR (1) | BR112012003955A2 (enExample) |
| CA (1) | CA2771594C (enExample) |
| ES (1) | ES2534326T3 (enExample) |
| IL (1) | IL217903A (enExample) |
| IN (1) | IN2012DN01325A (enExample) |
| MX (1) | MX2012002059A (enExample) |
| NZ (1) | NZ597983A (enExample) |
| PL (1) | PL2467387T3 (enExample) |
| WO (1) | WO2011021038A1 (enExample) |
| ZA (1) | ZA201200910B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597983A (en) | 2009-08-20 | 2014-05-30 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| EA026134B1 (ru) * | 2010-12-16 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Трициклические ингибиторы pi3k и способы их применения |
| AU2015268776B2 (en) * | 2010-12-16 | 2017-04-13 | Genentech, Inc. | Tricyclic PI3k inhibitor compounds and methods of use |
| ES2661510T3 (es) | 2011-12-15 | 2018-04-02 | Novartis Ag | Uso de inhibidores de la actividad o función de PI3K |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| CN113943306A (zh) | 2012-09-20 | 2022-01-18 | Udc 爱尔兰有限责任公司 | 供电子应用的氮杂二苯并呋喃和包含氮杂二苯并呋喃的电子器件 |
| US9676765B2 (en) | 2012-11-07 | 2017-06-13 | Karus Therapeutics Limited | Histone deacetylase inhibitors and their use in therapy |
| HK1214159A1 (zh) | 2012-11-08 | 2016-07-22 | Rhizen Pharmaceuticals S.A. | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 |
| AR095443A1 (es) * | 2013-03-15 | 2015-10-14 | Fundación Centro Nac De Investig Oncológicas Carlos Iii | Heterociclos condensados con acción sobre atr |
| SI2994465T1 (sl) | 2013-05-10 | 2018-10-30 | Karus Therapeutics Limited | Novi inhibitorji histon deacetilaze |
| US9814037B2 (en) * | 2013-06-28 | 2017-11-07 | Intel Corporation | Method for efficient channel estimation and beamforming in FDD system by exploiting uplink-downlink correspondence |
| CN104557955B (zh) * | 2013-10-23 | 2017-05-03 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的三环类化合物，其制备方法和用途 |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| HRP20220227T1 (hr) * | 2015-12-16 | 2022-04-29 | Genentech, Inc. | Postupak priprave tricikličnih spojeva inhibitora p13k i postupci upotrebe navedenih spojeva u liječenju raka |
| KR102474326B1 (ko) | 2016-06-22 | 2022-12-05 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| EP3558309B1 (en) | 2016-11-07 | 2023-07-26 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| EP3534901B1 (en) | 2016-11-07 | 2022-06-22 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| JP7097623B2 (ja) | 2016-11-07 | 2022-07-08 | ヴァンダービルト ユニヴァーシティ | ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子 |
| GB201702938D0 (en) | 2017-02-23 | 2017-04-12 | Univ Southampton | Methods of generating and screening compartmentalised peptides libraries |
| TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
| WO2019113174A1 (en) | 2017-12-05 | 2019-06-13 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
| IL316472A (en) | 2018-01-10 | 2024-12-01 | Recurium Ip Holdings Llc | Benzamide compounds |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| WO2022169882A1 (en) | 2021-02-03 | 2022-08-11 | Verge Analytics, Inc. | Methods and treatment of viral infection caused by sars-cov-2 |
| CN117751127B (zh) * | 2021-08-20 | 2026-07-03 | 南京大美生物制药有限公司 | 一种五元含氮杂环并杂芳基类衍生物及其用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| WO2002002551A1 (en) | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| EP1521747B1 (en) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Receptor-type kinase modulators and methods of use |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| JP2008545660A (ja) | 2005-05-20 | 2008-12-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼ阻害剤として有用なピロロピリジン化合物 |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| KR20090021155A (ko) | 2006-04-26 | 2009-02-27 | 에프. 호프만-라 로슈 아게 | Ｐｉ3ｋ 억제제로서의 피리미딘 유도체 |
| AU2007243466B2 (en) * | 2006-04-26 | 2012-01-19 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them |
| WO2008001076A1 (en) | 2006-06-26 | 2008-01-03 | Ucb Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
| EP2441768A1 (en) | 2006-11-13 | 2012-04-18 | Eli Lilly & Co. | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
| EP2121613A2 (en) | 2007-01-31 | 2009-11-25 | Vertex Pharmaceuticals, Inc. | 2-aminopyridine derivatives useful as kinase inhibitors |
| EP2139332A4 (en) | 2007-03-28 | 2010-04-21 | Merck Sharp & Dohme | SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS |
| EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| WO2009094224A1 (en) * | 2008-01-25 | 2009-07-30 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| JP2011529932A (ja) | 2008-08-05 | 2011-12-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ナフチリジン及び医薬としてのその使用 |
| WO2010037765A2 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| US8981087B2 (en) | 2009-07-29 | 2015-03-17 | Karus Therapeutics Limited | Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| NZ597983A (en) | 2009-08-20 | 2014-05-30 | Karus Therapeutics Ltd | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| DK3686193T3 (da) | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| EP3181564B1 (en) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| SI2994465T1 (sl) | 2013-05-10 | 2018-10-30 | Karus Therapeutics Limited | Novi inhibitorji histon deacetilaze |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514756D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
-
2010
- 2010-08-19 NZ NZ597983A patent/NZ597983A/en not_active IP Right Cessation
- 2010-08-19 EP EP10747483.5A patent/EP2467387B1/en active Active
- 2010-08-19 AU AU2010286168A patent/AU2010286168B2/en not_active Ceased
- 2010-08-19 ES ES10747483.5T patent/ES2534326T3/es active Active
- 2010-08-19 CA CA2771594A patent/CA2771594C/en not_active Expired - Fee Related
- 2010-08-19 US US13/388,164 patent/US9200007B2/en active Active
- 2010-08-19 IN IN1325DEN2012 patent/IN2012DN01325A/en unknown
- 2010-08-19 PL PL10747483T patent/PL2467387T3/pl unknown
- 2010-08-19 MX MX2012002059A patent/MX2012002059A/es active IP Right Grant
- 2010-08-19 CN CN201080036402.7A patent/CN102498115B/zh active Active
- 2010-08-19 JP JP2012525212A patent/JP5746172B2/ja active Active
- 2010-08-19 BR BR112012003955A patent/BR112012003955A2/pt not_active Application Discontinuation
- 2010-08-19 WO PCT/GB2010/051370 patent/WO2011021038A1/en not_active Ceased
-
2012
- 2012-02-02 IL IL217903A patent/IL217903A/en active IP Right Grant
- 2012-02-07 ZA ZA2012/00910A patent/ZA201200910B/en unknown
-
2015
- 2015-10-22 US US14/920,410 patent/US9580442B2/en active Active
-
2017
- 2017-01-19 US US15/410,114 patent/US9938290B2/en active Active
-
2018
- 2018-03-01 US US15/909,011 patent/US10501478B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2771594C (en) | 2018-05-01 |
| IL217903A0 (en) | 2012-03-29 |
| MX2012002059A (es) | 2012-04-19 |
| WO2011021038A1 (en) | 2011-02-24 |
| EP2467387B1 (en) | 2015-01-07 |
| US20180009826A1 (en) | 2018-01-11 |
| US9938290B2 (en) | 2018-04-10 |
| ZA201200910B (en) | 2013-05-29 |
| US20120178737A1 (en) | 2012-07-12 |
| US9200007B2 (en) | 2015-12-01 |
| JP2013502404A (ja) | 2013-01-24 |
| JP5746172B2 (ja) | 2015-07-08 |
| US9580442B2 (en) | 2017-02-28 |
| US10501478B2 (en) | 2019-12-10 |
| AU2010286168B2 (en) | 2014-05-15 |
| US20160108057A1 (en) | 2016-04-21 |
| BR112012003955A2 (pt) | 2017-09-26 |
| IN2012DN01325A (enExample) | 2015-06-05 |
| PL2467387T3 (pl) | 2015-08-31 |
| ES2534326T3 (es) | 2015-04-21 |
| US20190040079A1 (en) | 2019-02-07 |
| CA2771594A1 (en) | 2011-02-24 |
| IL217903A (en) | 2017-08-31 |
| AU2010286168A1 (en) | 2012-03-08 |
| CN102498115A (zh) | 2012-06-13 |
| CN102498115B (zh) | 2016-12-07 |
| EP2467387A1 (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012002059A (es) | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. | |
| NZ605627A (en) | Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase | |
| PH12015500666A1 (en) | Pyrazolopyrimidine jak inhibitor compounds and methods | |
| PH12014500599B1 (en) | Protein kinase inhibitors | |
| NZ605528A (en) | Ip receptor agonist heterocyclic compounds | |
| NZ601847A (en) | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor | |
| PH12013500661A1 (en) | FURO[3,2-d]PYRIMIDINE COMPOUNDS | |
| MX2010008686A (es) | Derivado de pirrolopirimidina como inhibidor de fosfatidilinositol 3-quinasa y uso del mismo. | |
| MX2013002558A (es) | Derivado de imidazol de heteroanillo fusionado que tiene efecto de activacion de proteina cinasa activada por monofosfato de adenosina (amk). | |
| TN2013000394A1 (fr) | Derives de pyrrolo [2,3-d] pyrimidine servant d'inhibiteurs de kinases apparentees a la tropomyosine | |
| PH12012501643A1 (en) | Pyrazolopyrimidine compounds and their use as pde 10 inhibitors | |
| EP2288260A4 (en) | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD | |
| MX369801B (es) | Compuesto heterociclico sustituido con halogeno. | |
| GEP20156267B (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | |
| GEP201606507B (en) | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors | |
| MX2009004244A (es) | Derivados de pteridina como inhibidores de cinasa tipo polo utiles en el tratamiento de cancer. | |
| NZ599342A (en) | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | |
| WO2010144499A3 (en) | Urea derivatives as kinase inhibitors | |
| NZ723502A (en) | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | |
| PH12012500355A1 (en) | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors | |
| MX2011011516A (es) | Compuestos farmaceuticos. | |
| NZ592314A (en) | Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine | |
| MX2009008386A (es) | Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer. | |
| IN2012DN00770A (enExample) | ||
| NZ605558A (en) | Benzamide derivatives and their use as hsp90 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 19 AUG 2017 BY AJ PARK Effective date: 20140922 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 AUG 2018 BY CPA GLOBAL Effective date: 20170706 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 AUG 2019 BY CPA GLOBAL Effective date: 20180705 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 AUG 2020 BY CPA GLOBAL Effective date: 20190704 |
|
| LAPS | Patent lapsed |